Want to see SE:ALZ full AI Analyst Report?

Alzinova AB (ALZ) Price & Analysis

2 Followers

ALZ Stock Chart & Stats

kr0.82

-kr0.14(-4.96%)

At close: Mar 06 4:00 PM EST

kr0.82

-kr0.14(-4.96%)

Day’s Range― - ―

52-Week Rangekr0.37 - kr2.21

Previous CloseN/A

Volume98.89K

Average Volume (3M)2.34M

Market Cap

kr145.25M

Enterprise Valuekr66.43

Total Cash (Recent Filing)kr13.31M

Total Debt (Recent Filing)kr800.00K

Price to Earnings (P/E)―

Beta0.74

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding324,224,880

10 Day Avg. Volume4,029,489

30 Day Avg. Volume2,341,633

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio-2.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.26

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageMinimal debt and extremely low leverage reduce financial risk while preserving flexibility to fund research, pursue partnerships, or withstand development delays. This balance-sheet structure is supportive over the next several quarters because limited debt service avoids additional pressure on already negative operating cash flow.

Growing Equity BaseThe larger equity base provides a stronger capital foundation for advancing clinical and preclinical programs. Although it does not eliminate future financing needs, increased equity supports funding capacity and gives the company more flexibility to continue development without relying heavily on debt.

Proprietary Alzheimer’s PlatformA proprietary antigen platform focused on amyloid-beta oligomers gives Alzinova a defined technology base across vaccine-based and antibody-based approaches. If development progresses, this platform could support multiple candidates and create partnering or commercialization opportunities.

Bears Say

Persistent Operating LossesDeeply negative operating profit and net income show that the company remains far from breakeven. Continued losses can consume the capital base, constrain investment choices, and increase dependence on successful clinical progress or external funding before sustainable earnings are possible.

Sustained Cash BurnNegative operating and free cash flow indicate that ongoing research and investment require funding beyond internally generated cash. The deterioration in free cash flow versus the prior period raises the likelihood that additional capital will be needed to maintain development over the coming quarters.

Unreliable Revenue BaseLow and volatile revenue provides limited support for the current cost base and makes financial planning less predictable. Without a consistent commercial revenue stream, Alzinova remains primarily dependent on development progress and potential partnering or financing to fund its business.

ALZ FAQ

What was Alzinova AB’s price range in the past 12 months?

Alzinova AB lowest stock price was kr0.37 and its highest was kr2.21 in the past 12 months.

What is Alzinova AB’s market cap?

Alzinova AB’s market cap is kr145.25M.

When is Alzinova AB’s upcoming earnings report date?

Alzinova AB’s upcoming earnings report date is Nov 12, 2026 which is in 52 days.

How were Alzinova AB’s earnings last quarter?

Alzinova AB released its earnings results on Aug 20, 2026. The company reported -kr0.033 earnings per share for the quarter.

Is Alzinova AB overvalued?

According to Wall Street analysts Alzinova AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alzinova AB pay dividends?

Alzinova AB does not currently pay dividends.

What is Alzinova AB’s EPS estimate?

Alzinova AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alzinova AB have?

Alzinova AB has 324,224,880 shares outstanding.

What happened to Alzinova AB’s price movement after its last earnings report?

Alzinova AB reported an EPS of -kr0.033 in its last earnings report. Following the earnings report the stock price went down -6.925%.

Which hedge fund is a major shareholder of Alzinova AB?

Currently, no hedge funds are holding shares in SE:ALZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alzinova AB

Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.